Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.37 |
| ▸ | BCDIN3D | Q7Z5W3 | 6/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065937 | 0.78 | GAA (0.35) | KCNN4KIF11 | |
| SCHEMBL4204205 | 0.78 | ALDH1A1 (0.41) | LPAR1VNN1HPGDMAPK1 | |
| SCHEMBL6065962 | 0.78 | LPAR1 (0.36) | KCNN4BCDIN3DLPAR1VNN1CYP1A2 | |
| SCHEMBL6133264 | 0.77 | KCNN4 (0.37) | KCNN4BCDIN3DACSS2KIF11BRD4 | |
| SCHEMBL4205063 | 0.77 | ALDH1A1 (0.36) | KCNN4BCDIN3DACSS2BRD4BRD9 | |
| SCHEMBL20539675 | 0.77 | HPGD (0.41) | KCNN4CYP1A2CYP3A4CYP2D6LMNA | |
| SCHEMBL17853170 | 0.77 | KDM4C (0.42) | KCNN4LPAR1VNN1 | |
| SCHEMBL6065837 | 0.77 | LPAR1 (0.37) | BRD4BRD9BPTFKAT2BLPAR1 | |
| SCHEMBL5147620 | 0.76 | KIF11 (0.36) | KCNN4BCDIN3DACSS2KIF11BRD4 | |
| SCHEMBL3119092 | 0.75 | LPAR1 (0.38) | BRD4BRD9BPTFKAT2BLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1663245-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| WO-2005027909-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2005-03-31 | — | — | WO | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | KCNN4 3757/4885BCDIN3D 3844/4885ACSS2 1009/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | KCNN4 3863/4885BCDIN3D 3426/4885ACSS2 1294/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | KCNN4 2885/4885BCDIN3D 2114/4885ACSS2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.